• Figure 3 Photomicrograph of cytologic specimen obtained by EUS-guided showing a poorly differentiated carcinoma with histological features consistent with a metastasis from his previous hepatocellular carcinoma (Papanicolaou stain, × 200). (wjgnet.com)
  • B: Microscopic examination revealed metastatic hepatocellular carcinoma in the pancreas (HE, × 40). (wjgnet.com)
  • Locally advanced or metastatic hepatocellular carcinoma (HCC). (medscape.com)
  • Advanced hepatocellular carcinoma, pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer. (medscape.com)
  • It was also under development for the treatment of metastatic pancreatic adenocarcinoma, gastric cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma. (globaldata.com)
  • It was also under development for the treatment of epithelial ovarian cancer peritoneal cancer, fallopian tube cancer, metastatic pancreatic cancer, hepatocellular carcinoma, bone cancer and bladder cancer. (pharmaceutical-technology.com)
  • Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin's lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. (fox4kc.com)
  • Liver metastases are not the same as cancer that starts in the liver, which is called hepatocellular carcinoma . (medlineplus.gov)
  • Patients with these advanced unresectable or metastatic tumors that have progressed while on, or since finishing, the last treatment can join a phase 2 study assessing a three-drug combination of immunotherapy pembrolizumab (Keytruda), belzutifan (Welireg), an HIF-2a inhibitor, and kinase-inhibitor lenvatinib (Lenvima). (medscape.com)
  • Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting. (onclive.com)
  • Enrollment criteria stipulate that patients must have histologically or cytologically confirmed advanced, unresectable, or metastatic non-hematologic tumors with an NRG1 fusion, with any coding gene as the fusion partner. (onclive.com)
  • Katelyn T. Byrne, PhD, of the Perelman School of Medicine at the University of Pennsylvania, discusses the first in-depth analysis of the impact of selicrelumab, an anti-CD40 antibody, which was found to enrich T cells in pancreatic tumors, activate the immune system, and alter the tumor stroma (Abstract CT005). (ascopost.com)
  • The study is enrolling patients with advanced/metastatic solid tumors, who have exhausted approved treatment options. (fox4kc.com)
  • In pancreatic cancer, about 95% of the tumors are KRAS mutated, on codon 12 2 . (cancertreatmentjournal.com)
  • Although rare in other types of solid tumors, KRAS G12R is commonly found in pancreatic cancer as high as 15-20% 4 . (cancertreatmentjournal.com)
  • Pancreatic neuroendocrine tumors display a range of clinical presentations and outcomes. (unina.it)
  • Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. (unina.it)
  • Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. (unina.it)
  • Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. (unina.it)
  • Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). (unina.it)
  • Most pancreatic cancers are exocrine tumors that develop from ductal and acinar cells. (msdmanuals.com)
  • Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the Surveillance, Epidemiology, and End Results Program. (cancercentrum.se)
  • My work on liquid biopsies has involved blood based protein signatures for pancreatic cancer, and single-cell morphometric, proteomic and genomic characterization of circulating tumor cells, in comparison to solid tumors. (lu.se)
  • It is indicated for metastatic adenocarcinoma of the pancreas as first-line treatment in combination with gemcitabine. (medscape.com)
  • Irinotecan liposomal is used in combination with fluorouracil and leucovorin for metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. (medscape.com)
  • Gross section of an adenocarcinoma of the pancreas measuring 5 × 6 cm resected from the pancreatic body and tail. (medscape.com)
  • The RT approach in this trial was considered low-dose and antiquated by contemporary standards due to the use of a split-course technique and the use of large treatment fields, which encompassed the entire pancreas/pancreatic bed and the celiac, pancreaticosplenic, peripancreatic, and retroperitoneal regional lymph nodes. (cancernetwork.com)
  • The frequency of metastasis to the pancreas is limited, and the frequency of metastasis of a squamous cell carcinoma of the esophagus is limited even further. (spandidos-publications.com)
  • Complete simultaneous resections of esophageal squamous cell carcinoma and a solitary metastasis to the pancreas is beneficial and may produce favorable outcomes. (spandidos-publications.com)
  • Approximately 75% of all pancreatic carcinomas occur within the head or neck of the pancreas, 15-20% occur in the body of the pancreas, and 5-10% occur in the tail. (medscape.com)
  • Gross section of an adenocarcinoma of the pancreas measuring 5 X 6 cm resected from the pancreatic body and tail. (medscape.com)
  • By using immunohistochemistry we investigated the expression of EphA2 and EphrinA-1 in 217 early squamous cell cervical carcinomas and examine their prognostic relevance. (medsci.org)
  • The increased levels of EphA2 and EphrinA-1 in a relative high number of early stage squamous cell carcinomas suggested that these two proteins may play an important role in the development of a subset of early cervical cancers. (medsci.org)
  • It proved to be a valid biomarker especially in detecting squamous intraepithelial lesions in cervical liquid-based samples and in discerning these lesions from their mimickers, as well as in ovarian, endometrial, vulvar, primary and metastatic melanomas, breast, pancreatic and renal cell carcinomas. (medsci.org)
  • Genetic analysis has recently identified four pancreatic cancer subtypes -- squamous, pancreatic progenitor, aberrantly differentiated endocrine exocrine (ADEX), and immunogenic. (medicinenet.com)
  • 6.02 has demonstrated pre-clinical activity in multiple tumor types, including breast cancer, colorectal cancer, pancreatic cancer, and head and neck squamous cell carcinoma. (pharmiweb.com)
  • New devices have demonstrated significant results for the treatment of medical conditions, including mild-to-moderate acne vulgaris, wound healing, psoriasis, squamous cell carcinoma in situ (Bowen's disease), basal cell carcinoma, actinic keratosis, and cosmetic applications. (researchgate.net)
  • To construct a prognostic signature composed of DNA repair genes to effectively predict the prognosis of patients with head and neck squamous cell carcinoma (HNSCC). (frontiersin.org)
  • Head and neck squamous cell carcinoma (HNSCC) is a type of tumor that originates from the squamous epithelium of the head and neck areas, including the mucous membranes of the lips, tongue, pharynx, larynx, and others ( 1 ). (frontiersin.org)
  • Characterize the "stroma-tumor cell" crosstalk in NSCLC and the role of tumor fibroblasts in the tumorigenesis of both major NSCLC subtypes: adenocarcinoma (ADC) and squamous cell carcinoma (SQC). (clinicbarcelona.org)
  • Since no other obvious distal metastases were observed, the patient underwent simultaneous surgical procedures, excising the esophageal squamous cell carcinoma and the pancreatic metastasis. (spandidos-publications.com)
  • A histopathological examination confirmed squamous cell carcinoma in both specimens. (spandidos-publications.com)
  • This is a Phase II, open-label, multi-center study to determine the efficacy and safety of MEDI4736 evaluated as single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on fluoropyrimidine containing or gemcitabine-containing first-line chemotherapy.This study will consist of Part A, lead-in, as well as a possible expansion Part B. (astrazenecaclinicaltrials.com)
  • Zepzelca is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. (pharmaceutical-technology.com)
  • Chemotherapy for metastatic pancreatic cancer can extend the life and improve the quality of life, but it rarely cures the patient. (medicinenet.com)
  • Olaparib has US Food and Drug Administration (FDA) approval for adults with germline BRCA -mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. (medscape.com)
  • It is indicated for maintenance treatment of adults with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. (medscape.com)
  • Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. (canceropole-est.org)
  • In this article, we review the data surrounding the use of chemotherapy (CT) and chemoradiotherapy (CRT) in patients with resectable pancreatic cancer. (cancernetwork.com)
  • To evaluate intrinsic and acquired mechanisms of resistance to chemotherapy and targeted agents in metastatic colorectal cancer, in the three genotypes (KRAS/NRAS mutant, BRAF mutant and triple-WT). (clinicbarcelona.org)
  • Patients with metastatic grade 3 neoplasia are usually treated with chemotherapy but have a poor progression-free and overall survival. (nih.gov)
  • Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature. (cdc.gov)
  • Erlotinib has been approved by the FDA for use, in combination with gemcitabine, as a first-line treatment for locally advanced, unresectable, or metastatic pancreatic cancer. (medscape.com)
  • To prospectively evaluate efficacy and tolerance of the 5-fluorouracil + folinic acid + cisplatin (LV5FU2-P) combination in the treatment of unresectable pancreatic carcinoma. (nih.gov)
  • 69 patients with nonmetastatic colorectal cancer (non-mCRC) and 57 with metastatic CRC (mCRC) were enrolled to evaluate the prognostic value of serum albumin (ALB), serum lactate (SLA), and lactate dehydrogenase (LDH) in patients with metastatic CRC. (hindawi.com)
  • Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. (canceropole-est.org)
  • AG-2 is highly expressed and secreted in malignant cancer types, including breast carcinomas, pancreatic cancer , glioblastoma, prostate cancer and metastatic colorectal cancer . (medchemexpress.com)
  • Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). (cdc.gov)
  • Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). (cdc.gov)
  • Adult patients with this cancer who have received at least one prior systemic therapy - no more than two in the metastatic setting - are being recruited for a National Cancer Institute (NCI) phase 2 study testing two immune therapies with and without a MEK inhibitor, cobimetinib (Cotellic). (medscape.com)
  • Xiaoran determined that Semaphorin 3F can repel pancreatic cancer cells and prevent metastasis in the liver in mouse models of orthotopic pancreatic carcinoma. (navbo.org)
  • This Preceptorship has been a unique opportunity to learn about the emerging data and discuss the open questions in the treatment of metastatic bladder and kidney cancer. (esmo.org)
  • Few patients diagnosed with pancreatic cancer have identifiable risk factors. (medicinenet.com)
  • Pancreatic cancer is highly lethal because it grows and spreads rapidly and often is diagnosed in its late stages. (medicinenet.com)
  • Pancreatic cancer may be difficult to diagnose until late in its course. (medicinenet.com)
  • Symptoms and signs of pancreatic cancer in its late stage include weight loss and back pain . (medicinenet.com)
  • In some cases, painless jaundice may be a symptom of early pancreatic cancer that can be cured with surgery. (medicinenet.com)
  • Patients diagnosed with pancreatic cancer are encouraged to seek out clinical trials that will ultimately improve pancreatic cancer treatment. (medicinenet.com)
  • Many organizations exist to help provide information and support for patients and families fighting pancreatic cancer. (medicinenet.com)
  • An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 ASCO Annual Meeting (Abstract 5544). (ascopost.com)
  • There are few, if any, more difficult clinical challenges than pancreatic cancer, a disease that continues to confound the oncology community's quest for cure. (ascopost.com)
  • The study estimates that pancreatic cancer is on course to become the. (ascopost.com)
  • Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. (ascopost.com)
  • The advent of effective combination chemotherapies has changed the treatment landscape for metastatic pancreatic cancer, extending median survival and leading to durable responses in a subset of patients. (ascopost.com)
  • The most active agents for pancreatic cancer have been 5-fluorouracil (5-FU) and gemcitabine. (medscape.com)
  • Response rates are typically less than 20% in pancreatic cancer. (medscape.com)
  • Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Pharmaceuticals SA , announced today the official opening of a Phase 1B clinical trial for the oral therapeutic GZ17-6.02 (6.02) in combination with capecitabine in patients with metastatic breast cancer. (pharmiweb.com)
  • Based on this data, in addition to the robust preclinical data, we are optimistic that 6.02 in combination with capecitabine in patients with metastatic breast cancer may provide increased benefit over single-agent capecitabine. (pharmiweb.com)
  • I am delighted to be participating in the trial of G217-6.02 as I'm very excited to be able to offer metastatic breast cancer patients a highly novel super-enhancer inhibitor therapy that holds great promise in the studies conducted to date," said Dr. O'Shaughnessy. (pharmiweb.com)
  • This is an important milestone for Genzada Pharmaceuticals and we are excited to partner with Dr. O'Shaughnessy and Texas Oncology to work toward bringing about additional treatment options for patients with advanced or metastatic hormone positive breast cancer," said Dr. Bailes. (pharmiweb.com)
  • The team took a collaborative approach to designing the trial while leveraging TD2's extensive experience in metastatic breast cancer to help guide the clinical strategy to focus on patients most likely to get clinical benefit. (pharmiweb.com)
  • Both the incidence and the death rates for pancreatic cancer are increasing. (medscape.com)
  • The initial manifestations of pancreatic cancer are often nonspecific, and consequently are often misinterpreted. (medscape.com)
  • Pancreatic cancer is notoriously difficult to diagnose in its early stages. (medscape.com)
  • Laboratory findings in patients with pancreatic cancer are usually nonspecific. (medscape.com)
  • Occasionally, the presence of pancreatic cancer is suggested by elevated liver transaminase, bilirubin, and alkaline phosphatase levels on testing performed for other purposes. (medscape.com)
  • Patients with advanced pancreatic cancer and weight loss have laboratory evidence of malnutrition (eg, low serum albumin or cholesterol level). (medscape.com)
  • Surgery is the only potentially curative treatment modality for early-stage pancreatic cancer. (medscape.com)
  • In the fight against pancreatic cancer, clinical trials often provide the best treatment options. (pancan.org)
  • My husband was diagnosed with pancreatic cancer to the liver (stage 4) on April 28, 2014. (pancan.org)
  • Connect with other caregivers for information, support and inspiration through the Pancreatic Cancer Action Network's Survivor & Caregiver Network. (pancan.org)
  • If you have any questions about pancreatic cancer, contact PanCAN Patient Services for free, personalized and in-depth disease information and resources. (pancan.org)
  • No one should face pancreatic cancer alone. (pancan.org)
  • Get the latest news and updates from the Pancreatic Cancer Action Network. (pancan.org)
  • are the trademarks of the Pancreatic Cancer Action Network, Inc. (pancan.org)
  • Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. (pancan.org)
  • The Pancreatic Cancer Action Network's tax identification number is #33-0841281. (pancan.org)
  • The 5-year overall survival of patients with pancreatic cancer is approximately 5%, with potentially resectable disease representing the curable minority. (cancernetwork.com)
  • Further therapeutic advances and prospective trials are needed to better define the optimal role of adjuvant and neoadjuvant treatment in patients with resectable pancreatic cancer. (cancernetwork.com)
  • Pancreatic cancer is the fourth leading cause of cancer-related death in the United States and accounts for roughly 40,000 deaths each year. (cancernetwork.com)
  • However, all these mouse strains display residual immune functions, in particular, natural killer (NK) cells that can inhibit tumor formation and metastatic spread of cancer cells ( 20 , 21 ). (iiarjournals.org)
  • Indeed, NSG mice have been shown to be better recipients than NOD/SCID, nude or other immunodeficient mouse strains for developing and studying various xenograft models of human cancer, such as melanoma ( 20 , 26 , 27 ), leukemia ( 28 ), pancreatic ( 29 ), cervical ( 30 ) and breast cancer ( 31 ). (iiarjournals.org)
  • Between March 1998 and June 2000, 35 patients, mean age 61 years (37-75), with advanced (n=2) or metastatic (n=33) pancreatic cancer and initial performance status (WHO) of 0 (n=9), 1 (n=14) or 2 (n=12) were enrolled in the study. (nih.gov)
  • It should be compared to gemcitabine as a first line therapy in advanced and metastatic pancreatic cancer. (nih.gov)
  • In this web-based program, physicians will learn how recent developments in multimodal therapies have advanced the management of metastatic pancreatic cancer. (broadcastmed.net)
  • Pancreatic cancer is one of the more increasingly common solid tumor malignancies in western countries with an overall survival of 9-10% at 5 years 1 . (cancertreatmentjournal.com)
  • As the rate of pancreatic cancer has steadily increased over the past decade, so has its presentations with colonic metastases. (cancertreatmentjournal.com)
  • Synchronous presentation of pancreatic cancer with colonic metastases are rare, with only a few reported cases in the literature to date. (cancertreatmentjournal.com)
  • Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). (jamanetwork.com)
  • To identify novel biomarkers predictive of survival and/or treatment response in pancreatic cancer, cholangiocarcinoma, esophagus cancer and gastric cancer. (clinicbarcelona.org)
  • p27 expression is reduced in pancreatic adenocarcinomas and decreased protein levels of p27 may play a role in the differentiation of pancreatic cancer. (biomedcentral.com)
  • Pancreatic cancer is a malignant tumor with an extremely poor prognosis. (biomedcentral.com)
  • Recent studies denoted that alterations in growth factors and growth factor receptors seem to influence the biologic behaviour of pancreatic cancer cells [ 2 ]. (biomedcentral.com)
  • Pancreatic cancer is the fourth leading cause of cancer deaths, being responsible for 7% of all cancer-related deaths in both men and women. (medscape.com)
  • The initial symptoms of pancreatic cancer are often quite nonspecific and subtle in onset. (medscape.com)
  • Surgery is the primary mode of treatment for pancreatic cancer. (medscape.com)
  • Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer related death. (biomedcentral.com)
  • We developed a high-throughput 3D cell culture drug screening system for pancreatic cancer, which displays a strongly increased chemoresistance. (biomedcentral.com)
  • Metastatic breast cancer means that the cancer has already sent metastases to other parts of the body, most often the bones, lungs, liver or brain. (docrates.com)
  • At Docrates, the treatment of metastatic breast cancer is always customised individually, utilising the expertise of the multidisciplinary team of physicians. (docrates.com)
  • The treatment of metastatic breast cancer is always customised individually, while the choice of treatments and the expected treatment response depend on various factors, such as the biological characteristics of the tumour, previous treatments, treatment outcome and adverse effects, the general condition of the patient, symptoms and other potential illnesses. (docrates.com)
  • The options available for metastatic breast cancer treatment include drug therapy, radiotherapy and sometimes even surgery . (docrates.com)
  • In the treatment of metastatic breast cancer it is also important to weigh the potential benefits against the side effects caused by the treatment. (docrates.com)
  • Only a few percent of Finnish breast cancer patients are initially diagnosed with metastatic disease. (docrates.com)
  • However, breast cancer may recur later in the form of metastatic breast cancer. (docrates.com)
  • In the care of metastatic breast cancer, discussion of treatment options with an oncologist immediately after the diagnosis has been ascertained as well as seamless collaboration between the experienced care team members are both of utmost importance. (docrates.com)
  • Pancreatic cancer is often locally and distally aggressive, but initial presentation as cecal perforation is uncommon. (biomedcentral.com)
  • However, pancreatic cancer initially presenting with cecal perforation secondary to large bowel obstruction from local colon invasion is distinctly uncommon. (biomedcentral.com)
  • Cancerul pancreatic Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose neuroendocrine cancer causes. (pcmaster.ro)
  • Pancreatic cancer primary tumor size measurements are often discordant between CT and pathologic specimen after resection. (medscape.com)
  • Symptoms of pancreatic cancer such as pain and weight loss are nonspecific, leading to a later diagnosis by which time the disease has spread. (msdmanuals.com)
  • Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. (cdc.gov)
  • Patients and Methods Screening outcomes were collected from three European centers that conduct prospective screening in high-risk groups including families with clustering of PDAC (familial pancreatic cancer [FPC]) or families with a gene defect that predisposes to PDAC. (medscape.com)
  • The results from this prevali- the field of cancer biomarkers (11-13), and that approach was dation study showed that patients could be classified into high- adopted here to define predictive serum biomarkers associated versus low-risk groups for developing metastatic breast cancer with tumor relapse in breast cancer patients. (lu.se)
  • The main clinical problem in treating NB is metastasis, specifically metastatic stages III and IV according to the International Neuroblastoma Staging System ( 1 , 2 ), because metastatic lesions are often resistant to current therapies. (iiarjournals.org)
  • The percentage of patients with involved site of metastasis at the time of first systemic therapy initiation for metastatic disease are presented. (jamanetwork.com)
  • Our findings suggest that in pancreatic carcinoma, TGF-β1 expression is related to tumor growth and metastasis. (biomedcentral.com)
  • All patients underwent curative resection of pancreatic adenocarcinoma without evidence of intraperitoneal disease. (cancernetwork.com)
  • Hepatic resection in 485 R0 pT2 and pT3 cases of advanced carcinoma of the gallbladder: results of a Japanese Society of Biliary Surgery survey--a multicenter study. (cancercentrum.se)
  • Thirteen individuals with FPC (6.1%) underwent surgical resection for a suspected PRL, but only four (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intraepithelial neoplasms). (medscape.com)
  • Advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). (medscape.com)
  • Argani, P. Intraductal spread by metastatic islet cell tumor (well-differentiated pancreatic endocrine neoplasm) involving the breast of a child, mimicking a primary mammary carcinoma. (hopkinsmedicine.org)
  • This cell line was established from a metastatic liver tumor of human pancreatic carcinoma. (tohoku.ac.jp)
  • The primary tumor responsible for this metastatic nodule was not contained within the surgical specimen. (biomedcentral.com)
  • Two individuals (0.9%) in the FPC cohort had a pancreatic tumor, including one advanced PDAC and one early grade 2 neuroendocrine tumor. (medscape.com)
  • A clinical trial of vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma was negative in a prospective, randomised, double-blind, multicentre phase 2 trial. (wikipedia.org)
  • Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma. (cancercentrum.se)
  • Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumours that compose 1-2% of all pancreatic tumours. (nih.gov)
  • Pulmonary carcinoids are well differentiated low to intermediate grade lung neuroendocrine tumours (LNETs), that belong to the group of lung neuroendocrine neoplasms which also include highly aggressive lung neuroendocrine carcinomas (LNECs). (who.int)
  • Over the past decades pancreatic ductal adenocarcinoma (PDAC) has become the subject of increased research activity, however, the prognosis of this disease remains the worst amongst solid tumours. (biomedcentral.com)
  • Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. (cdc.gov)
  • Is lung involvement a favorable prognostic factor for pancreatic ductal adenocarcinoma with synchronous liver metastases? (lu.se)
  • Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. (medscape.com)
  • Although pulmonary carcinoids show relatively good prognosis in comparison to carcinomas, metastatic disease and relapse do occur. (who.int)
  • Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. (jamanetwork.com)
  • 1] Patients generally present with locally advanced or metastatic disease that precludes cure, since symptoms frequently prompt the diagnosis in the absence of effective screening strategies. (cancernetwork.com)
  • Histological evaluation determined this was locally invasive pancreatic adenocarcinoma, and therefore the true etiology of the original cecal perforation. (biomedcentral.com)
  • Transplantation in the management of metastatic endocrine tumours. (unina.it)
  • Moertel CG, Lefkopoulo M, Lipsitz S, Hah RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. (unina.it)
  • Glucose measurements are used in the diagnosis and treatment of pancreatic islet cell carcinoma and of carbohydrate metabolism disorders, including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia. (cdc.gov)
  • His official diagnosis was "poorly differentiated (anaplastic) carcinoma" metastatic to the liver. (pancan.org)
  • The new World Health Organisation 2017 classification distinguished well-differentiated grade 3 neuroendocrine tumours from poorly differentiated grade 3 neuroendocrine carcinomas. (viamedica.pl)
  • A hypermetabolic mass in the pancreatic head and liver metastases. (pancan.org)
  • Liver metastases and a pancreatic tail lesion were seen, and the hepatic metastases were biopsied. (cancertreatmentjournal.com)
  • According to the WHO 2017 classification, they are divided into neuroendocrine tumours (NETs) G3 and neuroendocrine carcinomas (NECs). (nih.gov)
  • Most of the studies focused on grade 1 and grade 2 neuroendocrine tumours, mainly of pancreatic origin. (viamedica.pl)
  • This study aimed to evaluate response and survival parameters and compare outcomes of treatment of neuroendocrine tumours and carcinomas. (viamedica.pl)
  • The progression-free survival for patients with neuroendocrine tumours was 15.3 months (95% CI: 3.9-30.4), and for patients with neuroendocrine carcinomas it was 3.3 months (95% CI: 2.5-7.1). (viamedica.pl)
  • Median overall survival was 22 months (95% CI: 11.8-22.0) and 4.6 months (95% CI: 2.2-5.9) for patients with tumours and carcinomas, respectively. (viamedica.pl)
  • Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. (jamanetwork.com)
  • Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. (jamanetwork.com)
  • Urothelial carcinoma (UC) is one the most common malignancies derived from the urothelium of the lower urinary tract. (medsci.org)
  • Clinical impact of pancreatic metastases from renal cell carcinoma: a multicenter retrospective analysis. (jamanetwork.com)
  • Clinical evaluation, imaging studies, indications for cytologic study and preprocedural requirements for duct brushing studies and pancreatic fine-needle aspiration: The Papanicolaou Society of Cytopathology Guidelines. (cancercentrum.se)
  • Worldwide, cervical carcinoma is the second most frequent malignancy among women and the death rate is 8 per 100,000 [ 1 ]. (medsci.org)
  • In our previous study of cervical carcinomas FIGO stage I-IV we found that increase expression of EphA2 and EphrinA-1 was significantly associated with shorter overall survival in multivariate analysis [ 22 ]. (medsci.org)
  • Overall survival was calculated from time of first systemic therapy initiation for metastatic disease to death from any cause or censored at the time of last follow-up. (jamanetwork.com)
  • The purpose of our study was to investigate the immunohistochemical expression of TGF-β1 and p27 in pancreatic adenocarcinomas and to compare the findings with the clinicopathological features and survival. (biomedcentral.com)
  • The treatment did not overcome the aggressive character of neuroendocrine carcinomas and resulted in low response and survival outcomes in comparison to those achieved in tumour therapy. (viamedica.pl)
  • Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. (unina.it)
  • Factors influencing recurrence after surgical treatment for T2 gallbladder carcinoma. (cancercentrum.se)
  • Because cytology alone is not highly sensitive for detection of low grade urothelial carcinoma and recurrence of the disease, several adjunct markers and urine based tests for urothelial carcinoma have been developed, which can help in the final diagnosis. (medsci.org)